Scarica l'app Stockscreener
0.6451
1.21%
-0.0079
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - ulpravda.ru
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - ulpravda.ru
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - ulpravda.ru
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - ulpravda.ru
Bearish Setup: Will Atossa Therapeutics Inc. stock maintain growth storyJuly 2025 Decliners & High Accuracy Investment Entry Signals - ulpravda.ru
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study By Investing.com - Investing.com India
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for - GuruFocus
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial - TipRanks
Atossa Therapeutics Receives FDA Approval for Metastatic Breast Cancer Study - TradingView — Track All Markets
FDA clears new breast cancer study testing (Z)-endoxifen candidate - Stock Titan
Reviewing Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) - Defense World
Seattle InnoDiagrid emerges from stealth I Atossa troubles - The Business Journals
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average – Should You Sell? - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Norwich Bulletin
Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey - Defense World
Will Atossa Therapeutics Inc. stock outperform international peersChart Signals & Community Consensus Trade Alerts - Улправда
Earnings Report: Is Atossa Therapeutics Inc. stock a buy before product launchesTake Profit & Smart Money Movement Tracker - Улправда
Atossa Therapeutics Earnings Notes - Trefis
Will Atossa Therapeutics Inc. stock maintain growth storyBond Market & Free AI Powered Buy and Sell Recommendations - DonanımHaber
Will Atossa Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Technical Pattern Based Signals - Улправда
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category - BioSpace
Atossa Therapeutics Wins R&D Excellence Award for Precision Endocrine Therapy Innovation - Clinical Trials Arena
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Atossa Therapeutics (ATOS) Highlights Promising (Z)-endoxifen Tr - GuruFocus
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium - WV News
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
Atossa gains on rare pediatric disease status for Duchenne asset - MSN
Atossa Therapeutics, Inc. (ATOS) -6.4% in After-hours: Shares Slip Amid Routine Trading - Stocks Telegraph
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy - BioSpace
Volume Recap: Will Atossa Therapeutics Inc stock return to pre crisis levelsMarket Trend Review & Target Return Focused Picks - moha.gov.vn
Atossa Therapeutics (ATOS) Stock: Soars 8% as FDA Grants Rare Pediatric Disease Designation for (Z)-Endoxifen (ATOS) - parameter.io
Why Are Shares Of Atossa Therapeutics Up Today? - Benzinga
Atossa Therapeutics (ATOS) Surges on FDA Pediatric Designation - GuruFocus
Atossa gains on Rare Pediatric Disease status for Duchenne asset - Seeking Alpha
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status - Investing.com UK
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status By Investing.com - Investing.com Nigeria
Atossa Therapeutics (ATOS) Gains FDA Recognition for Duchenne Mu - GuruFocus
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):